Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway
- PMID:17671189
- DOI: 10.1158/0008-5472.CAN-07-0599
Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway
Abstract
In tumor cells, cyclin E deregulation results in the appearance of five low molecular weight (LMW) isoforms. When overexpressed in breast cancer cells, these forms of cyclin E induce genomic instability, resistance to inhibition by p21 and p27, and resistance to antiestrogen therapy. Additionally, the LMW forms of cyclin E strongly correlate with decreased survival in patients with breast cancer. However, the oncologic role of the LMW forms of cyclin E in breast cancer tumorigenesis is yet to be determined. To this end, we generated transgenic mice expressing full-length cyclin E alone (M46A), full-length and the EL4 isoforms (EL1/EL4), or the EL2/3 isoforms of cyclin E (T1) under the control of the mouse mammary tumor virus promoter. Compared with full-length cyclin E, LMW cyclin E overexpression induces delayed mammary growth during the pubertal phase and abnormal cell morphology during lactation. Both primary mammary tumor formation and metastasis were markedly enhanced in LMW cyclin E transgenic mice. LMW cyclin E overexpression in mammary epithelial cells of mice is sufficient by itself to induce mammary adenocarcinomas in 34 of 124 (27%) animals compared with 7 of 67 (10.4%) mice expressing only the full-length cyclin E (P < 0.05). In addition, metastasis was seen in 25% of LMW cyclin E tumor-bearing animals compared with only 8.3% of tumors in the full-length cyclin E background (P < 0.05). Moreover, LMW cyclin E overexpression selects for inactivation of p53 by loss of heterozygosity and spontaneous and frequent inactivation of ARF. Therefore, LMW cyclin E overexpression strongly selects for spontaneous inactivation of the ARF-p53 pathway in vivo, canceling its protective checkpoint function and accelerating progression to malignancy.
Similar articles
- The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.D'Amico M, Wu K, Di Vizio D, Reutens AT, Stahl M, Fu M, Albanese C, Russell RG, Muller WJ, White M, Negassa A, Lee HW, DePinho RA, Pestell RG.D'Amico M, et al.Cancer Res. 2003 Jun 15;63(12):3395-402.Cancer Res. 2003.PMID:12810676
- [Research on expression and control of p16 and p21 by wild-type p53 gene in two lung adenocarcinoma cell lines].Jin Y, Yan CH, Wu Y, Liu Y, Zhang GY, Li P, Fu SB.Jin Y, et al.Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Oct;20(5):409-12.Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003.PMID:14556194Chinese.
- Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression.Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, Fukasawa K.Kawamura K, et al.Cancer Res. 2004 Jul 15;64(14):4800-9. doi: 10.1158/0008-5472.CAN-03-3908.Cancer Res. 2004.PMID:15256449
- p53-Dependent and -independent functions of the Arf tumor suppressor.Sherr CJ, Bertwistle D, DEN Besten W, Kuo ML, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF.Sherr CJ, et al.Cold Spring Harb Symp Quant Biol. 2005;70:129-37. doi: 10.1101/sqb.2005.70.004.Cold Spring Harb Symp Quant Biol. 2005.PMID:16869746Review.
- The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model.Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE.Donehower LA, et al.Prog Clin Biol Res. 1996;395:1-11.Prog Clin Biol Res. 1996.PMID:8895979Review.No abstract available.
Cited by
- Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.Cooley A, Zelivianski S, Jeruss JS.Cooley A, et al.Cell Cycle. 2010 Dec 15;9(24):4900-7. doi: 10.4161/cc.9.24.14158. Epub 2010 Dec 15.Cell Cycle. 2010.PMID:21150326Free PMC article.
- A novel interaction between HER2/neu and cyclin E in breast cancer.Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK.Mittendorf EA, et al.Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.Oncogene. 2010.PMID:20453888Free PMC article.
- The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing.Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL.Nguyen HH, et al.Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19750-5. doi: 10.1073/pnas.0806581105. Epub 2008 Dec 8.Proc Natl Acad Sci U S A. 2008.PMID:19064917Free PMC article.
- Too much cleavage of cyclin E promotes breast tumorigenesis.Loeb KR, Chen X.Loeb KR, et al.PLoS Genet. 2012;8(3):e1002623. doi: 10.1371/journal.pgen.1002623. Epub 2012 Mar 29.PLoS Genet. 2012.PMID:22479209Free PMC article.No abstract available.
- A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S.Mitri Z, et al.Invest New Drugs. 2015 Aug;33(4):890-4. doi: 10.1007/s10637-015-0244-4. Epub 2015 May 7.Invest New Drugs. 2015.PMID:25947565Clinical Trial.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous